会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • IMMUNOGLOBULIN E COMPETITOR
    • 免疫球蛋白E竞争者
    • WO1989004834A1
    • 1989-06-01
    • PCT/GB1988001018
    • 1988-11-18
    • RESEARCH CORPORATION LIMITEDGOULD, Hannah, JaneHELM, Birgit, AnnaMARSH, Philip, John, Henry, Benedict
    • RESEARCH CORPORATION LIMITED
    • C07K07/00
    • C07K16/00A61K38/00C07K16/4291
    • A polypeptide competitor or analogue for human Immunoglobulin E (IgE) low affinity sites comprises a polypeptide which has a sequence of amino acid which has a sequence of amino acids which is shown in Table I. This amino acid sequence corresponds to amino acids 340 to 439 of the epsilon heavy chain of IgE. A particularly preferred polypeptide competitor has a sequence of amino acids corresponding to amino acids 340 to 547 of the epsilon heavy chain of IgE as set out in Table V herein, which also shows the corresponding DNA sequence coding therefor. Such a polypeptide may also include additional short sequences at the beginning and/or end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to compete with native IgE for the low affinity receptor sites on human cells. The polypeptide may be produced synthetically or by expression from Escherichia coli containing a plasmid having a DNA segment coding for the polypeptide.
    • 用于人免疫球蛋白E(IgE)低亲和位点的多肽竞争剂或类似物包含具有氨基酸序列的多肽,其氨基酸序列如表I所示。该氨基酸序列对应于氨基酸340至439 的IgE重链。 特别优选的多肽竞争剂具有对应于本文表V中列出的IgE的ε重链的氨基酸340至547的氨基酸序列,其也显示了编码的相应DNA序列。 这样的多肽还可以在核心序列的起始和/或末端包括生理上无害的附加短序列,并且对核心序列与天然IgE与人细胞上的低亲和力受体位点竞争的能力没有贡献。 多肽可以由含有编码多肽的DNA区段的质粒的大肠杆菌合成或表达产生。
    • 5. 发明申请
    • MEDICINAL COMPOSITION
    • 药物组合物
    • WO1987001286A1
    • 1987-03-12
    • PCT/GB1986000507
    • 1986-08-27
    • RESEARCH CORPORATION LIMITEDGILCHRIST, ThomasMANSON, William
    • RESEARCH CORPORATION LIMITED
    • A61K37/18
    • A61K38/018A61M1/1654A61M1/287Y10S530/832Y10S530/833
    • A medicinal composition, particularly but not exclusively for use in fluids for medical dialysis, contains, as an agent for maintaining the osmolality of the fluid, a protein hydrolysate resulting from the action of a proteolytic enzyme on the sodium caseinate fraction of milk protein. The enzyme is preferably trypsin but other proteolytic enzymes and enzyme mixtures may be used, examples being chymotrypsin, pancreatin and pronase. The method of production involves treating the sodium caseinate in aqueous medium with the enzyme at the appropriate pH and temperature for optimum enzyme activity. The product of the enzymic hydrolysis, after filtration through a bacterial filter, adjustment of the osmolality to an appropriate level of around 300 mOsm/Kg and the pH to physiological level of about 6.6 and addition of physiological salt levels, constitutes the final product.
    • 特别但不排他地用于医疗透析用流体的药物组合物含有由蛋白水解酶对乳蛋白的酪蛋白酸钠级分作用而产生的蛋白质水解物作为维持流体渗透压的试剂。 该酶优选为胰蛋白酶,但也可使用其他蛋白水解酶和酶混合物,例如胰凝乳蛋白酶,胰酶和链霉蛋白酶。 生产方法包括在适当的pH和温度下用酶处理含水介质中的酪蛋白酸钠,以获得最佳的酶活性。 酶水解的产物通过细菌过滤器过滤后,将重量克分子渗透压浓度调节至约300mOsm / Kg的适当水平,pH至6.6的生理水平并加入生理盐水平构成最终产物。
    • 7. 发明申请
    • INOSITOL PHOSPHATE ANALOGUES
    • INOSITOL磷酸酯类似物
    • WO1988007047A1
    • 1988-09-22
    • PCT/GB1988000186
    • 1988-03-10
    • RESEARCH CORPORATION LIMITEDPOTTER, Barry, Victor, Lloyd
    • RESEARCH CORPORATION LIMITED
    • C07F09/177
    • C07F9/177Y02P20/55
    • Novel inositol phosphorothioates have the general formula (I) C6H6(OH)n[(OPO2S) ]m[(OPO2O) ]6-m-n in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6. They may be prepared by a method comprising reacting an inositol derivative having the general formula (II) C6H6(OB)n[OP(OCH2CH2CN)2]6-n in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur, which may or may not be radioactive, in a solvent therefor, and removing the hydroxyl-protecting groups from the product of the reaction. Phosphate esters may be prepared by oxidising the compound of formula (II) with an organic peroxide.
    • 新的肌醇硫代磷酸酯具有通式(I)C 6 H 6(OH)n [(OPO 2 S)2 - ] m [(OPO 2 O)2 - ]] 6-nn,其中n为0或1至5的整数, m为1〜6的整数。它们可以通过包括使具有通式(II)的C6H6(OB)n [OP(OCH2CH2CN)2] 6-n的肌醇衍生物与其中n为0或 B为1〜5的整数,B表示羟基保护基,在其溶剂中可含或不具有放射性的元素硫溶液,并从反应产物中除去羟基保护基。 磷酸酯可以通过用有机过氧化物氧化式(II)的化合物来制备。
    • 10. 发明申请
    • COMPLEMENT-BINDING PEPTIDE
    • 补充结合肽
    • WO1988007054A1
    • 1988-09-22
    • PCT/GB1988000213
    • 1988-03-18
    • RESEARCH CORPORATION LIMITEDWINTER, Gregory, PaulDUNCAN, Alexander, Robert
    • RESEARCH CORPORATION LIMITED
    • C07K07/00
    • C07K16/00
    • A polypeptide, having the ability to inhibit complement mediated lysis, consists of or contains the amino acid sequence (I): -X-A-Y-A-Z-, in which X is a polar amino acid, A is any amino acid; Y is a basic amino acid, and Z is a basic amino acid. In a preferred embodiment the polypeptide has the general formula (II): Head-X-A-Y-A-Z-Tail, in which X is Asn, Glu, Thr or Gln, Y and Z are, independently, Lys or Arg, 'Head' is a hydrogen atom or a sequence of amino acid residues attached to the amino group of the adjacent amino acid X, 'Tail' is a hydrogen atom or a sequence of amino acid residues attached to the carboxyl group of the adjacent amino acid Y, and, each of the groups represented by A, which may be the same or different, is an amino acid residue.
    • 具有抑制补体介导的裂解能力的多肽由X或A-Y-A-Z-组成或含有其中X为极性氨基酸的氨基酸序列(I),A为任何氨基酸; Y是碱性氨基酸,Z是碱性氨基酸。 在优选的实施方案中,多肽具有通式(II):头XAYAZ-尾,其中X是Asn,Glu,Thr或Gln,Y和Z独立地是Lys或Arg,'头'是氢原子 或连接于相邻氨基酸X的氨基的氨基酸残基的序列,“尾”是与相邻氨基酸Y的羧基相连的氢原子或氨基酸残基的序列, 由A表示的可以相同或不同的基团是氨基酸残基。